Manufacturer · 2026
Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514
Caliway Biopharmaceuticals (2026). Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514. Company press release.
Company press release
Source: https://www.caliwaybiopharma.com/en/news-detail/-CBL-514-SUPREME-01-FPI-ObesityWeek-2026-ENG/
Last reviewed . By the PeptIQ team.
Peptides linked in PeptIQ Wiki
This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.